Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China

KPC-producing Klebsiella pneumoniae (KPC-KP) is the most widely spread carbapenem-resistant Enterobacteriaceae (CRE) in China. Avibactam is a novel non-β-lactam β-lactamase inhibitor which is highly active against KPC. Recently, ceftazidime-avibactam (CAZ-AVI) was approved for clinical treatment in...

Full description

Bibliographic Details
Main Authors: Xiaoyan Cui, Bin Shan, Xue Zhang, Fen Qu, Wei Jia, Bin Huang, Hua Yu, Yi-Wei Tang, Liang Chen, Hong Du
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Microbiology
Subjects:
KPC
Klebsiella pneumoniae
ceftazidime-avibactam
antimicrobial susceptibility
antimicrobial resistance
Online Access:https://www.frontiersin.org/article/10.3389/fmicb.2020.01365/full

Internet

https://www.frontiersin.org/article/10.3389/fmicb.2020.01365/full

Similar Items